The funds will be used to advance Genespire’s leading-edge platform technologies towards the development of novel gene therapies in primary immunodeficiencies and metabolic genetic diseases.
Lead Product(s): Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sofinnova Partners
Deal Size: $17.3 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 29, 2020